Previous Article | Next Article ![]()
Molecular and Cellular Biology, July 2000, p. 4532-4542, Vol. 20, No. 13
Unité de Virologie et d'Immunologie
Cellulaire, URA CNRS 1930,1 and
Unité de Biologie Moléculaire de l'Expression
Génique, URA 1773 CNRS,2 Institut Pasteur,
75724 Paris Cedex 15, France
Received 11 February 2000/Returned for modification 21 March
2000/Accepted 27 March 2000
The interferon (IFN)-induced double-stranded RNA-activated protein
kinase PKR mediates inhibition of protein synthesis through phosphorylation of the The double-stranded RNA
(dsRNA)-activated protein kinase PKR is a serine/threonine protein
kinase which is present in most cells at basal levels and which can be
induced upon interferon (IFN) treatment (22, 42, 50). Its
best-characterized substrate is the PKR was also reported by different but convergent experiments to be
involved in transcriptional stimulation through activation of the
NF- NF- I In order to study the mechanism by which PKR stimulates gene expression
through NF- Plasmids.
Plasmid pcDNA1/Amp expressing PKRwt or its
catalytically inactive form PKR/KR296 has been previously described
(44). The pHIV-1 LTR-luc plasmid, corresponding to the
full-length human immunodeficiency virus type 1 (HIV-1) long terminal
repeat (LTR), and the pHIV-1 LTR Construction of a PKR deletion mutant.
The plasmid
BluescriptSK (PKRwt) (42) was cut with BclI and
AflII to remove the PKR region located between subdomains IV and VI. The resulting PKR truncation plasmid was religated between the
BclI and AflII sites with the use of a 25-bp
adapter obtained by annealing two complementary oligonucleotides of
sense strand sequence: 5'-AACTTGATCATCGCGAGATCTTAAG-3'. This
adapter was designed to contain an internal NruI digestion
site (TCG/CGA) which will give a blunt end in addition to restoring an
arginine residue (CGA codon) in the PKR sequence at its original
position (residue 412). The religated plasmid, designated
BluescriptSK(PKR-Nru), was cut with BclI and
NruI. This construct contains all of the PKRwt sequence
except for a 100-amino-acid gap between residues 312 and 412.
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
PKR Stimulates NF-
B Irrespective of Its Kinase
Function by Interacting with the I
B Kinase Complex
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
subunit of eukaryotic initiation factor 2 (eIF2
) and is also involved in the induction of the IFN gene through
the activation of the transcription factor NF-
B. NF-
B is retained
in the cytoplasm through binding to its inhibitor I
B
. The
critical step in NF-
B activation is the phosphorylation of I
B
by the I
B kinase (IKK) complex. This activity releases NF-
B from
I
B
and allows its translocation to the nucleus. Here, we have
studied the ability of PKR to activate NF-
B in a reporter assay and
have shown for the first time that two catalytically inactive PKR
mutants, PKR/KR296 and a deletion mutant (PKR/Del42) which lacks the
potential eIF2
-binding domain, can also activate NF-
B. This
result indicated that NF-
B activation by PKR does not require its
kinase activity and that it is independent of the PKR-eIF2
relationship. Transfection of either wild-type PKR or catalytically
inactive PKR in PKR0/0 mouse embryo fibroblasts resulted in
the activation of the IKK complex. By using a glutathione
S-transferase pull-down assay, we showed that PKR interacts
with the IKK
subunit of the IKK complex. This interaction apparently
does not require the integrity of the IKK complex, as it was found to
occur with extracts from cells deficient in the NF-
B essential
modulator, one of the components of the IKK complex. Therefore, our
results reveal a novel pathway by which PKR can modulate the NF-
B
signaling pathway without using its kinase activity.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
subunit of eukaryotic
initiation factor 2 (eIF2
), the phosphorylation of which leads to
inhibition of protein synthesis (21). PKR was shown to
phosphorylate eIF2
in yeast (8) or during a viral
infection in murine clones stably expressing PKR (44); for a
review, see reference 11. The use of these two in
vivo systems firmly established that PKR-mediated phosphorylation of
eIF2
is directly responsible for inhibition of cellular growth and
inhibition of viral growth, two properties related to the antiviral and
antiproliferative mechanisms of action of IFN.
B pathway (see below). This activity was initially suggested by
the observation that the PKR inhibitor 2-aminopurine could inhibit the
induction of the immediate-early genes c-myc and
c-fos as well as the induction of the beta IFN (IFN
) gene and IFN
-induced genes (65); for a review, see reference
58. More direct evidence was provided by in vivo
experiments where selective ablation of PKR mRNAs led to inhibition of
NF-
B activation in response to dsRNA (38). Moreover,
mouse embryo fibroblasts (MEFs) from PKR knockout mice
(PKR0/0) showed a much lower response than the
corresponding PKR+/+ MEFs for the induction of IFN
in
response to dsRNA (30, 60). These data collectively
implicate PKR as playing a role in the induction of genes, in addition
to regulating other metabolic events, such as protein translation,
through eIF2
phosphorylation. PKR has now also been shown to be
involved in some of the mechanisms leading to apoptosis, in particular,
in the response of cells to viral infection or to dsRNA treatment (for
a review, see reference 17). This property could be
due, at least in part, to the ability of PKR to activate NF-
B
(18).
B, first identified as a transcription factor required for
B-cell-specific gene expression, is essential in the cellular response
to inflammatory and stress signals (3, 28). NF-
B is
negatively regulated in the cytoplasm of unstimulated cells through
interaction at its nuclear localization sites with the I
B proteins.
This activity prevents its translocation to the nucleus and therefore
its ability to activate gene transcription (20). The NF-
B
transcription pathway is activated by proinflammatory cytokines, such
as tumor necrosis factor alpha and interleukin 1 (IL-1); by bacterial
or viral products, such as lipopolysaccharide (LPS), dsRNA, or the
human T-cell leukemia virus type 1 Tax protein; and by oxidative stress
molecules (2). All these stimuli trigger the phosphorylation
of I
B and its subsequent ubiquitination and degradation by the 26S
proteasome (1, 7, 61). As a consequence, NF-
B is
liberated and migrates to the nucleus.
B phosphorylation is achieved by a 700- to 900-kDa multimeric
complex, referred to as the I
B kinase (IKK) complex (15, 41,
48, 54, 63). IKK contains two catalytic subunits, IKK
and
IKK
, which can form homo- or heterodimers. Both kinases can be
activated upon phosphorylation by the NF-
B inducing kinase (36) and by the MAP kinase kinase kinase 1 (32).
Recent data show that IKK
is the major effector of I
B
phosphorylation in response to cytokines (24, 33, 55).
Another component of the multimeric IKK complex is the NF-
B
essential modulator (NEMO), which interacts with IKK
and regulates
the kinase activity of IKK (49). Mutant cell lines which do
not express NEMO cannot activate NF-
B in response to multiple
stimuli, such as the ones cited above (59).
B activation, we have used a functional microassay for
PKR with luciferase as a reporter gene under the control of NF-
B
response elements. In this assay, both wild-type PKR (PKRwt) and
inactive PKR mutants were used in cells either expressing the PKR gene
(PKR+/+ MEFs) or not expressing it (PKR0/0
MEFs). This strategy allowed us to demonstrate that the ability of PKR
to stimulate NF-
B-dependent gene expression is a property of PKR
independent of its kinase activity. Transfection of PKRwt and PKR
mutants in PKR0/0 cells allowed the activation of NF-
B
and of IKK, thus demonstrating that PKR does not require its kinase
function to activate IKK. Accordingly, a recent report has also
presented evidence that an inactive PKR mutant can activate IKK
(9). Finally, PKR was found to interact with the IKK
subunit of the complex in a glutathione S-transferase (GST)
pull-down assay. This finding indicates that PKR can act upstream of
the IKK signaling pathway and emphasizes its role in signaling for IFN production.
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
NF-
B-luc plasmid, corresponding
to the same region but with a deletion in the 26-bp segment spanning
the two NF-
B binding sites (16), were provided by N. Israel (Institut Pasteur, Paris, France). The plasmids Ig
Cona-luc
and Cona-luc (45), as well as pcDNA3 (hemagglutinin
epitope-tagged NEMO), were provided by A. Israel (Institut Pasteur).
The pGL2 HIV-1 LTR-luc plasmid was a gift from Anne Gatignol (Jewish
General Hospital, Montreal, Quebec, Canada). For the construction of
pCMV-Tax, the Tax sequence was copied by PCR from the vector
HTLoligophX (obtained from M. Nerenberg, Scripps Research Institute, La
Jolla, Calif.) with the primers AGATCCAAGCTTCCACCATG (5'
end) and TTAAGCTTCCTTTTCAGACT (3' end) tailed with
HindIII restriction sites. The PCR-amplified Tax DNA was
first subcloned in PcRII (Invitrogen), cut with HindIII, and inserted in a pCMV vector using a pCMV-Tat plasmid previously cut
with HindIII to remove the Tat sequence (pCMV-Tat was a
gift from M. Emerman, Hutchinson Cancer Research, Seattle, Wash.). The
pGEX-murine PKRwt plasmid was provided by S. Kadereit and B. R. G. Williams (Cleveland Clinic Foundation, Cleveland, Ohio). The
pcDNA3-IKK
and pcDNA3-Flag epitope-tagged IKK
plasmids were gifts
from M. Kroll and F. Arenzana-Seisdedos (Institut Pasteur).
RT-PCR of luciferase transcripts.
PKR0/0 cells
cultured in 10-cm petri dishes were transfected with 10 µg of pGL2
HIV-1 LTR-luc in the presence of various amounts of PKRwt or mutant PKR
using the calcium phosphate precipitation-glycerol shock technique.
Total RNA was extracted 24 h posttransfection with RNA-plus
extraction solution (Quantum-Bioprobe). After 30 min of DNase I
treatment, 10 µg of total RNA was submitted to reverse transcription
(RT) with an oligo(dT) primer. Five microliters of the RT reaction
mixture was used as a matrix to perform a PCR with the following
primers: 5' luc 1600 (5'-CCGCGAAAAAGTTGCGCGGAGGA-3') and 3' UTR SV40
(5'-GGAGGAGTAGAATGTTGAGAGTCA-3'). The 3' UTR SV40 primer was designed to hybridize to a sequence located after the simian
virus 40 intron on the pGL2 plasmid in order to discriminate between
the DNA from the plasmid and the DNA obtained by PCR after RT of
Luc mRNA. An internal control RT-PCR was performed with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primers (gapdh+, 5' TGA AGG TCG GAG TCA ACG GAT TTG GT; gapdh
, 5' CAT GTG GGC CAT GAG GTC CAC CAC).
In vitro transcription and translation of PKR. The pcDNA1/Amp (PKR) plasmids (wt, KR296, and Del42) were linearized with BamHI. Transcription from the T7 promoter in the presence of the cap analog 7-mGpppG was carried out using an mRNA capping kit (Stratagene). The in vitro-transcribed mRNAs were translated in a rabbit reticulocyte lysate (Stratagene) using 10 µg of template RNA in the presence of 20 µCi of [35S]methionine/cysteine (ProMix; Amersham) and 6 mM 2-aminopurine (Sigma) in a 25-µl reaction volume. After 60 min of incubation at 30°C, the samples were analyzed by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) either directly or after subsequent analysis [immunoprecipitation or binding to poly(I)-poly(C)-agarose].
Immunoprecipitation of PKR. In vitro-translated PKR was incubated with anti-PKR monoclonal antibody 71/10 (31) in 200 µl of BI buffer (20 mM Tris-HCl [pH 7.6], 50 mM KCl, 400 mM NaCl, 1 mM EDTA, 1% Triton X-100, 5 mM 2-mercaptoethanol, 1% aprotinin [Sigma], 0.2 mM phenylmethylsulfonyl fluoride [PMSF], 20% glycerol). After 60 min of incubation at 4°C, 50 µl of protein A/G-agarose (Protein AG PLUS-agarose; Santa Cruz Biotechnology) was added, and the samples were further incubated overnight at 4°C. After three cycles of centrifugation (4°C, 3,000 × g) and resuspension in BI buffer, the samples were either directly analyzed after separation of the proteins by SDS-PAGE or used for in vitro phosphorylation of PKR.
Immunoprecipitation of IKK.
For immunoprecipitation with
anti-IKK
and anti-IKK
polyclonal antibodies (sc-7218 and sc-7607,
respectively; Santa Cruz) or with anti-NEMO antibody (59),
cell extracts were prepared in buffer L (20 mM Tris-HCl [pH 7.6], 50 mM KCl, 40 mM NaCl, 1 mM EDTA, 1% Triton X-100, 3 mM
-mercaptoethanol, 1% aprotinin, 0.2 mM PMSF, 25% glycerol)
containing sodium orthovanadate (Na3VO4) (1 mM), para-nitrophenyl phosphate (PNPP) (10 mM),
-glycerophosphate (10 mM), and sodium fluoride (NaF) (5 mM) as
phosphatase inhibitors. Cell extracts were incubated overnight at 4°C
with the desired antibodies previously bound to protein A/G-agarose (1 µl of antibody for 30 µl of agarose). After three cycles of
centrifugation (4°C, 3,000 × g) and resuspension in
buffer L-phosphatase inhibitors, the samples were used in in vitro
phosphorylation assays.
In vitro phosphorylation of PKR.
The immunoprecipitated in
vitro-translated PKR proteins (recovered by 50 µl of protein
A/G-agarose beads) were washed with BI buffer, further washed three
times with buffer II (20 mM Tris-HCl [pH 7.6], 100 mM KCl, 0.1 mM
EDTA, 1% aprotinin, 20% glycerol), and resuspended in buffer III
(buffer II supplemented with 2 mM MgCl2). For the
phosphorylation reaction, each sample was incubated with 40 µl of
buffer III supplemented with 2 mM MnCl2 and 10 µl of
[
-32P]ATP solution (1.25 mCi of
[
-32P]ATP per ml [3,000 Ci/mmol; ICN], 10 mM ATP,
and 1 mM MgCl2 in buffer II). The reaction was performed in
the absence or in the presence of 1 µg of poly(I)-poly(C) (Pharmacia)
per ml. After incubation for 15 min at 30°C, 2 µl (165 ng) of a
pure preparation of rabbit eIF2 complex (a gift from C. Proud,
University of Dundee, Dundee, United Kingdom) was added, and the
reaction was continued for another 15 min. An equal volume of 2× SDS
electrophoresis sample buffer was added, and the products were analyzed
by SDS-PAGE.
Cell cultures and transfections.
Human HeLa cells were grown
in Glutamax-1 Dulbecco's modified Eagle's medium (Gibco) supplemented
with 5 µg of penicillin-streptomycin per ml and containing 10% fetal
calf serum. PKR0/0 and PKR+/+ MEFs were
provided by B. R. G. Williams. They were cultured in the same
medium as HeLa cells. The 70Z/3 murine pre-B-cell line and the
NF-
B-unresponsive mutant 1.3E2 (NEMO deficient) were provided by G. Courtois and A. Israel. They were cultured in Glutamax-1 RPMI medium
(Gibco) supplemented with 5 µg of penicillin-streptomycin per ml and
50 µM
-mercaptoethanol and containing 10% fetal calf serum. For
microtransfection, 18 to 24 h before transfection, the cells were
seeded at 20,000 cells/well in 96-well microplates (Costar) with 200 µl of complete culture medium. At 3 h before transfection, the
medium was aspirated and replaced with fresh medium. The desired
amounts of plasmids were adjusted to the same final concentration with
the addition of pcDNA1/Amp and were transfected into the cells using
the calcium phosphate precipitation-glycerol shock technique as
previously described (43). At 48 h after transfection,
the culture medium was aspirated, and the cells were washed twice with
phosphate-buffered saline (PBS). Cells were then scraped and lysed in
140 µl of luc lysis buffer (25 mM Tris-phosphate [pH 7.6], 8 mM
MgCl2, 1 mM dithiothreitol [DTT], 0.1% Triton X-100,
15% glycerol) per well. For each sample, 100 µl was analyzed for
luciferase activity in a luminometer by automatic mixing with luc lysis
buffer solution containing 0.25 mM Luciferine (Sigma), 1 mM ATP,
and 1% bovine serum albumin (BSA). The protein content of each sample
was measured in 96-well microplates using a Bio-Rad Bradford kit and
the absorbance at 590 nm was determined in an LP400 spectrophotometer.
Each result corresponds to the average of four independent transfections.
Nuclear extracts.
PKR0/0 cells cultured in 10-cm
dishes were transfected with the different PKR constructs using the
calcium phosphate precipitation-glycerol shock technique. pCMV-Tax was
used as a positive control for the induction of NF-
B after
transfection. PKR0/0 cells were transfected with 250 ng or
1 µg of PKRwt or PKR/KR296 per plate in the presence of 10 µg of
pcDNA1/Amp. Four hours after transfection, the cells were submitted to
glycerol shock and then further incubated for 4 h in 2% serum
medium, after which they were scraped and washed with PBS. The pellet
was resuspended in 200 µl of electrophoretic mobility shift assay
(EMSA) I buffer (50 mM Tris-HCl [pH 7.9], 10 mM KCl, 1 mM EDTA, 0.2%
Nonidet P-40, 1 mM DTT, 1 mM PMSF, 1% aprotinin, 10% glycerol),
incubated for 1 min on ice, and centrifuged for 3 min at 6,000 × g and 4°C. The nuclear pellet was then resuspended in 20 µl of EMSA II buffer (20 mM HEPES [pH 7.9], 400 mM NaCl, 10 mM KCl,
1 mM EDTA, 1 mM DTT, 1 mM PMSF, 1% aprotinin, 20% glycerol),
incubated for 20 min on ice, and centrifuged for 10 min at 12,000 × g and 4°C. The nuclear extracts were collected and
stored at
80°C. The protein concentration was estimated using the
Bio-Rad Bradford kit.
EMSA.
Nuclear extracts (5 µg) were preincubated with
1 µg of poly(dI-dC) · poly(dI-dC) in 20 µl of binding
buffer (20 mM HEPES [pH 7.5], 70 mM NaCl, 2 mM DTT, 100 µg of BSA
per ml, 0.01% Nonidet P-40, 4% Ficoll) for 5 min at room temperature.
Then, 0.2 pmol of 32P-labeled NF-
B probe (30,000 cpm)
was added, and the extracts were further incubated for 20 min.
Complexes were resolved by electrophoresis at 180 V on a prerun 5%
native polyacrylamide gel in 0.5× Tris-borate-EDTA. The gel was dried
and exposed overnight for autoradiography in a PhosphorImager. For the
supershift assay, nuclear extracts were incubated for 10 min at room
temperature in binding buffer in the presence of 1 µl of anti-p50
(1157; a kind gift from N. Israel) or anti-p65 (sc-109; Santa Cruz)
polyclonal antibody prior to the addition of the probe.
IKK phosphorylation.
Cell extracts corresponding to
106 cells were immunoprecipitated with anti-NEMO antibody
previously used to coat 50 µl of protein A/G-agarose beads in
low-salt buffer (20 mM Tris [pH 7.6], 40 mM NaCl, 50 mM KCl, 1 mM
EDTA, 1% Triton X-100, 25% glycerol, 0.2 mM PMSF, 3 mM
2-mercaptoethanol, 10 µg of aprotinin per ml) containing 5 mM NaF, 10 mM PNPP, 1 mM Na3VO4, and 10 mM
-glycerophosphate. After overnight incubation at 4°C, the beads
were washed with low-salt buffer two times, washed once with kinase
buffer (see below) without ATP, and incubated with 40 µl of kinase
buffer (20 mM Tris-HCl [pH 7.6], 2 mM MgCl2, 2 mM
MnCl2, 10 µM ATP, 3 µCi of [
-32P]ATP
(3,000 Ci/mmol), 10 mM
-glycerophosphate, 10 mM NaF, 10 mM PNPP, 300 µM Na3VO4, 2 µM PMSF, 10 µg of aprotinin
per ml, 1 mM DTT) at 30°C for 30 min in the presence of 200 ng of
I
B
per reaction (I
B
was provided by M. Kroll and F. Arenzana-Seisdedos). An equal volume of 2× SDS electrophoresis sample
buffer was added, and the products were analyzed by SDS-PAGE.
Protein expression and purification.
Escherichia coli
BL21(DE3) cells containing the pGEX-murine PKR expression vector were
grown overnight at 37°C in 100 ml of Terrific Broth containing 100 µg of ampicillin per ml. After 1:50 dilution in 100 ml of fresh
medium, cells were grown at 30°C to an optical density of
approximately 0.5 (6 h) and induced with 0.5 mM
isopropyl-1-thio-
-D-galactopyranoside (IPTG) for an
additional 2 h. Bacteria were pelleted at 4,000 × g for 10 min at 4°C, resuspended in 5 ml of PBS containing 0.2 mM PMSF and 1 mM DTT, and frozen at
20°C overnight. After being
thawed on ice, the bacterial suspensions were frozen again in a dry
ice-methanol bath, thawed on ice, sonicated three times for 30 s
each time on ice, adjusted to 1% (wt/vol) with Triton X-100, and
centrifuged at 9,000 × g for 20 min at 4°C.
(HP1
is a nuclear protein [52]
[provided by J. Seeler]) was incubated overnight at 4°C with in
vitro-translated proteins in 200 µl of HNGT buffer (20 mM HEPES [pH
7.9], 150 mM NaCl, 10% glycerol, 0.1% Triton X-100). After three
washes with 500 µl of HNGT buffer, 20 µl of SDS sample buffer was
added, and the proteins were analyzed by SDS-PAGE.
| |
RESULTS |
|---|
|
|
|---|
NF-
B-dependent stimulation of gene expression by PKR is
independent of its protein kinase activity.
PKR is best known as a
strong inhibitor of protein synthesis; however, it can also stimulate
gene expression through NF-
B activation. In order to discriminate
between these two opposite properties, we have analyzed the effect of
different concentrations of PKR on the expression of
reporter-expressing plasmids dependent or not dependent on the presence
of NF-
B response elements. For this analysis, we chose a natural
NF-
B-responsive promoter, the HIV-1 LTR, and an artificial
construct, Ig
Cona, containing three NF-
B response elements cloned
upstream of a minimal promoter. The assay was performed with
PKR+/+ MEFs, and the effect of PKRwt was compared with that
of the catalytically inactive PKR/KR296 mutant (26, 44),
allowing us to determine whether the observed effect is related to the
kinase activity of PKR.
NF-
B-luc (Fig. 1A and C) and on the pair
Ig
Cona-luc-Cona-luc (Fig. 1B and D). PKRwt was found to stimulate
gene expression when transfected at low concentrations (0.2 to 1 ng of
the PKR plasmid for 100 ng of the reporter; transfection in 20,000 cells). This stimulatory effect, although not strong (two- to
threefold), was specific, since it could not stimulate pHIV-1
LTR
NF-
B-luc and Cona-luc, used as controls (Fig. 1A and B). Thus,
our assay can be used to monitor the NF-
B stimulation of gene
expression by PKR. Surprisingly, the PKR/KR296 mutant was also found to
stimulate the expression of pHIV-1 LTR-luc and Ig
Cona-luc, since
this stimulation was dependent on the presence of the NF-
B response
elements (Fig. 1C and D). These data illustrate that NF-
B-mediated
stimulation of gene expression by PKR does not require its kinase
activity. The lower stimulatory effect of PKRwt than of PKR/KR296 is
probably due to the ability of PKRwt to also inhibit the translation of the reporter gene (see below).
|
The PKR-eIF2
relationship is not required for PKR-mediated
stimulation of NF-
B-dependent gene expression.
Figure 1 shows
that when PKRwt was transfected at concentrations higher than 1 ng/well, it could inhibit gene expression. This result can be
attributed to its ability as a kinase to phosphorylate eIF2
, prevent
its normal recycling, and provoke arrest in protein synthesis. On the
other hand, when PKR/KR296 was transfected at concentrations higher
than 1 ng/well, the stimulation of the reporter continued to rise. The
stimulation appeared to be specific with regard to the presence or
absence of the NF-
B response elements in the promoters. However, the
possibility that PKR/KR296 upregulates the NF-
B-responsive reporter
gene by binding eIF2
and preventing access of eIF2
to PKR or
other eIF2
kinases could not be excluded. We therefore generated a
new PKR mutant, PKR/Del42, by removing 42 amino acids between
residues 369 and 412 in the catalytic subdomains V and VI (Fig.
2A). The rationale for this
deletion mutant construct was based on a sequence comparison which
revealed that this 42-amino-acid PKR motif could present an
-helix
structure similar to that of protein kinase A, known to bind its
pseudosubstrate inhibitor (27). Furthermore, this PKR domain
was shown to bind K3L, a vaccinia virus protein analog of the natural
PKR substrate eIF2
which acts as a pseudosubstrate inhibitor for PKR
(13). Consequently, this domain is the most susceptible
binding domain for eIF2
, and its deletion allows study of the
function of PKR independently of its interaction with its substrate.
|
, in contrast to PKRwt (Fig. 2E). The
PKR/Del42 mutant was assayed for its effect on the expression of the
pHIV-1 LTR-luc reporter plasmid using the same procedure as that
described for Fig. 1. The results show that, like PKRwt and PKR/KR296,
PKR/Del42 activated NF-
B (Fig. 2F).
NF-
B-dependent stimulation of gene expression in
PKR0/0 MEFs by PKRwt and the mutants PKR/KR296 and
PKR/Del42.
We next assayed the effects of PKRwt, PKR/KR296, and
PKR/Del42 on NF-
B activation after transfection in a cellular
PKR-free environment, i.e., in PKR0/0 MEFs. For each PKR
construct, we observed that the stimulation of the reporter was
dependent on the presence of the NF-
B response elements (Fig.
3A). This observation confirmed that PKR
does not need its kinase function to stimulate gene expression. The
fact that stimulation could take place in PKR0/0 cells
demonstrates that the stimulatory effect of mutant PKR is direct and
cannot be explained by sequestration of endogenous active PKR. It was
striking to note that, at high concentrations, PKRwt inhibited strongly
reporter expression, contrary to the PKR mutants (Fig. 1 and 3).
|
B-dependent
gene expression. Moreover, the use of different concentrations of PKRwt
allowed us to discriminate between the abilities of PKR to stimulate
and to inhibit gene expression. Finally, the use of different PKR
mutants revealed the intrinsic ability of PKR to stimulate
NF-
B-dependent gene expression in the absence of its kinase function.
NF-
B activation by PKRwt and catalytically inactive PKR in
EMSAs.
In order to confirm in an independent experiment that
catalytically inactive forms of PKR could activate NF-
B, we
performed a gel shift assay using cell extracts from PKR0/0
MEFs transfected with plasmids coding for PKRwt or PKR/KR296 (Fig.
4). These experiments were performed with
PKR0/0 cells in order to evaluate our data in response to
the expression of ectopically expressed PKR in a PKR-free environment.
Basal NF-
B activity was determined by transfection with the control pcDNA1/Amp vector. As expected, transfection of a plasmid encoding Tax,
a known NF-
B activator (57), led to NF-
B activation. Transfection of the PKRwt- or PKR/KR296-expressing plasmids revealed their ability to stimulate NF-
B. The identity of the complex retained on the probe as NF-
B was confirmed by a supershift assay using nuclear extracts from PKR/KR296-transfected cells (Fig. 4B).
|
B is in agreement with previous
reports (18, 29, 60). Moreover, our results reveal that
catalytically inactive PKR also brings about such activation.
PKRwt and catalytically inactive PKR activate the IKK complex.
In order to further investigate the mechanism by which PKR, either wild
type or mutant, activates NF-
B, we have assayed its effect on the
activation of the IKK complex. PKR0/0 cells were
transfected with plasmids expressing PKRwt or PKR/KR296, and the
IKK complex was immunoprecipitated from cytoplasmic extracts using
antibodies against NEMO, a component of the IKK complex necessary
for its assembly and activity (59). IKK activity was then
assayed in vitro by phosphorylation of I
B
as described previously
(41). Compared to LPS treatment or transfection with Tax,
transfection of both PKRwt and catalytically inactive PKR/KR296 efficiently activated IKK, whereas the transfection of a control vector
resulted in basal-level activation similar to that in untreated cells
(Fig. 5).
|
Interaction of PKR with the IKK complex.
Since PKRwt and
catalytically inactive PKR/KR296 both can activate NF-
B through
activation of the IKK complex, it is plausible to suggest that PKR
could activate NF-
B simply by interacting with the IKK complex.
antibodies.
The proteins, retained on the immunosorbent, were then analyzed for the
presence of PKR in immunoblots. The presence of IKK
and PKR in crude
extracts from HeLa cells and the increase in PKR levels after IFN
treatment are shown in Fig. 6A (left
side). Immunoblot analysis of the immunoprecipitates revealed that PKR could be recovered from the cell extracts by coimmunoprecipitation with
anti-IKK
antibodies. This coprecipitation was specific, since PKR
was not retained by the blank antibodies.
|
, IKK
, and NEMO. In addition, PKR/KR296 and
luciferase were included as controls. Nonspecific binding was
determined using GST-HP1
, a nuclear protein (52). The
results (Fig. 6B) revealed that, within the IKK complex, only the
IKK
subunit has the ability to bind specifically to GST-PKR. IKK
was found to bind similarly to GST-PKR and to the irrelevant GST protein. As a negative control, luciferase showed no binding to either
type of GST protein, while as a positive control, PKR/KR296 bound to
GST-PKR, in accord with its capacity to dimerize (for a review, see
reference 10). A small amount of PKR/KR296 could be
recovered from the irrelevant GST protein. This latter result was most
probably due to a nonspecific interaction, as was the case for IKK
.
In order to confirm the association between PKR and IKK
, we
performed another GST-PKR pull-down assay using cell extracts from the
murine NEMO-deficient cell line 1.3E2 and the corresponding parental
cell line 70Z/3 (12, 59). Yamaoka and colleagues have shown
that IKKs are not in a complex when the NEMO protein is absent, as in
the 1.3E2 cell line (59). The results (Fig. 6C) showed that
despite the difference in its localization, IKK
from both cell types
could bind to PKR and not to the irrelevant protein. It should be noted
that IKK
was detected as two bands with anti-IKK
polyclonal
antibodies in crude extracts from both NEMO-deficient cells (1.3E2) and
the corresponding parental cells (70Z/3) (10% input), whereas only one
of the bands could be detected after purification using GST-PKR. The
reason for this difference is not known and requires further analysis.
Whatever the case, the fact that PKR bound to similar amounts of IKK
in NEMO-deficient and parental cells suggests that this binding is
direct and does not require the integrity of the IKK structure.
| |
DISCUSSION |
|---|
|
|
|---|
The ability of PKR to activate NF-
B under various experimental
conditions has been reported by others (18, 38, 46, 60). In
this work, we have confirmed this finding and further demonstrated that
the PKR-mediated activation of NF-
B does not require its kinase function.
We first showed that defective kinase mutants of PKR activate the
expression of NF-
B-responsive reporter genes. The PKR constructs were found to stimulate the expression of luciferase placed under the
control of the HIV-1 LTR, whereas they had no effect on its expression
when placed under the control of HIV-1
NF-
B. Alternative possibilities to explain this increase in luciferase expression, such
as sequestration of endogenous PKR or competition for the substrate
eIF2
with other eIF2
kinases (19, 51), could be ruled
out. Indeed, activation of NF-
B was also observed in a PKR-free
environment (PKR0/0 MEFs) and even by the PKR/Del42 mutant,
which has a deletion of the region thought to bind eIF2
. The ability
of a catalytically inactive PKR to activate NF-
B was next confirmed
by EMSAs and by activation of the IKK complex. Finally, in vitro
protein-protein interaction experiments allowed us to show that PKR
binds specifically to the IKK
subunit of the IKK complex.
In a recent report, Chu et al. have shown that PKR/KR296 can activate
IKK
, either after cotransfection in 3T3 cells with an epitope-tagged
IKK
-expressing plasmid or by direct interaction with purified
proteins (9). The experiments that we have performed using
PKR0/0 cells clearly show the activation of the natural
endogenous IKK complex by both PKRwt and mutants and indicate that this
activation is independent of the kinase function of PKR.
The fact that inactive PKR mutants have the ability to activate NF-
B
through the activation of the IKK complex and the observation that PKR
can physically interact with this complex indicate that PKR can be used
as an adapter protein in this signaling pathway. Such a situation has
also been reported for two other kinases. (i) One is the RIP kinase
family, the members of which associate with the tumor necrosis factor
alpha signaling complex (23, 40, 62). RIP contains three
major domains: a kinase domain at its N terminus, an intermediate
domain, and a death domain at its C terminus. Use of different RIP
mutants and, in particular, their introduction into RIP-deficient cell
lines showed that NF-
B activation did not require the kinase domain
of RIP but did require the integrity of a charged domain located in its
intermediate domain (23, 56). In contrast, the death domain
of RIP was both necessary and sufficient for the induction of apoptosis
(23). (ii) Another example of the participation of a kinase
as an adapter protein is the IL-1 receptor-associated kinase IRAK. It
has recently been reported that catalytically inactive IRAK mutants can
restore IL-1 signaling in IL-1-unresponsive cell lines (34).
PKR is, however, best known as an inhibitor of protein synthesis
through its ability to phosphorylate eIF2
and, in this respect, belongs to the growing family of stress-activated eIF2
kinases, such
as GCN2, HRI, and PERK (5, 6, 14, 19, 53). Through this
ability to inhibit protein translation, PKR participates in the
antiviral action of IFN (44). Indeed, overexpression of PKR
after insertion at the nef gene site of an infectious HIV-1 genome proved to severely inhibit the growth of HIV-1 (4). Our results suggest that PKR may activate IKK through protein-protein interactions with the IKK
subunit. This notion is surprising, since
some signaling pathways can be activated through the inhibition of the
synthesis of repressors, as we have shown recently for c-Jun
NH2-terminal kinase (JNK) (25) (see below).
Therefore, activation of NF-
B through binding of PKR to IKK instead
of inhibition of the synthesis of an inhibitor for IKK is a novel mechanism.
NF-
B is one of the transcription factors necessary for IFN
induction, together with the IFN regulatory factors and the factor AP-1, itself dependent on the activation of JNK and the p38 MAP kinase
(37). The exact mechanism by which a viral infection triggers PKR to bind to IKK and activate NF-
B is not known; however, dsRNA could be involved in this process, since PKR-deficient cells have
been reported to be unresponsive to dsRNA for NF-
B activation (9, 30, 60).
Except for our reporter experiments performed with pHIV-1 LTR-luc,
which led to the transcription of dsRNA-containing transcripts (the
HIV-1 TAR region at the 5' end of luc mRNAs), we have not addressed
here the importance of dsRNA for PKR-mediated NF-
B or IKK
activation. All of our activation data were obtained after transfecting
the PKR plasmids alone in PKR0/0 MEFs. Similarly, the
PKR/KR296-mediated activation of IKK analyzed by Chu et al. was also
studied in the absence of added or transfected dsRNA (9).
Therefore, the exact mechanism by which viral infection or dsRNA
treatment leads to PKR docking to IKK remains an open question. It is
possible, however, that the binding of PKR to dsRNA is sufficient to
change the conformation of the protein (47) in a way that
favors its interaction with IKK
. It should be noted that the binding
of PKR to IKK
may not be sufficient to trigger IKK activation. We
have shown that PKR can bind IKK
from NEMO-deficient cells. However,
NEMO-deficient cells are unresponsive to dsRNA for NF-
B activation
(12, 59), although they do contain normal amounts of PKR
(M. C. Bonnet and E. F. Meurs, unpublished data). Therefore,
this result suggests that the PKR-mediated activation of NF-
B
through IKK
requires the presence of a complete IKK complex.
dsRNA has long been known to activate in IFN-treated cells,
independently of PKR, a pathway leading to the activation of a cytosolic RNase (RNase L) which can degrade diverse RNA substrates, including 18S and 28S rRNAs, thus inhibiting cellular protein synthesis
(35, 39, 64). We have recently shown, with the use of PKR-
and RNase L-deficient murine cells, that those cells were unresponsive
to JNK activation in response to dsRNA or virus infection, an effect
which could be linked to the defect in the regulation of translation by
PKR and RNase L (25). This result indicates that PKR and
RNase L are involved in the activation of JNK, probably through the
inhibition of a negative regulator for JNK, leading to the induction of
the IFN gene (25). Therefore, the participation of PKR in
the IFN system is dual: (i) as a kinase, it can regulate protein
synthesis, which both limits viral propagation and reinforces the
induction of IFN, through JNK activation; and (ii) as a protein, it
activates IKK by protein-protein interactions, leading to NF-
B
activation and the induction of the IFN gene, together with AP-1 and
the IFN regulatory factors (Fig. 7). In this respect, the nature of the PKR motifs involved in its interaction with IKK and the potential role of dsRNA in this interaction remain to
be investigated.
|
| |
ACKNOWLEDGMENTS |
|---|
We thank M. Kroll, F. Arenzana-Seisdedos, A. Gatignol, S. Ozden, G. Courtois, and A. Israel for reagents and helpful discussions.
This work was supported in part by a grant from the Agence Nationale de la Recherche sur le SIDA (ANRS 61852), Paris, France. M. Bonnet was supported by a grant from the Ministère de l'Enseignement, de la Recherche, et de la Technologie, Paris, France (MENRT).
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Unité de Virologie et d'Immunologie Cellulaire, URA CNRS 1930, Institut Pasteur, 28 rue du Dr Roux, 75724 Paris Cedex 15, France. Phone: 33 01 45 68 87 77. Fax: 33 01 40 61 30 12. E-mail: emeurs{at}pasteur.fr.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Alkalay, I.,
A. Yaron,
A. Hatzubai,
A. Orian,
A. Ciechanover, and Y. Ben-Neriah.
1995.
Stimulation-dependent I B phosphorylation marks the NF- B inhibitor for degradation via the ubiquitin-proteasome pathway.
Proc. Natl. Acad. Sci. USA
92:10599-10603 |
| 2. |
Baeuerle, P., and V. Baichwal.
1997.
NF- B as a frequent target for immunosuppressive and anti-inflammatory molecules.
Adv. Immunol.
65:111-136[Medline].
|
| 3. |
Baldwin, A.
1996.
The NF- B and I B proteins: new discoveries and insights.
Annu. Rev. Immunol.
14:649-681[CrossRef][Medline].
|
| 4. | Benkirane, M., C. Neuveut, R. F. Chun, S. M. Smith, C. E. Samuel, A. Gatignol, and K.-T. Jeang. 1997. Oncogenic potential of TAR RNA-binding TRBP and its regulatory interaction with protein kinase R. EMBO J. 16:611-624[CrossRef][Medline]. |
| 5. |
Berlanga, J. J.,
J. Santoyo, and C. De Haro.
1999.
Characterization of a mammalian homolog of the GCN2 eukaryotic initiation factor 2 kinase.
Eur. J. Biochem.
265:754-762[Medline].
|
| 6. |
Berlanga, J. J.,
S. Herrero, and C. De Haro.
1998.
Characterization of the hemin-sensitive eukaryotic initiation factor 2 kinase from mouse nonerythroid cells.
J. Biol. Chem.
273:32340-32346 |
| 7. |
Chen, Z.,
J. Hagler,
V. Palombella,
F. Melandri,
D. Scherer,
D. Ballard, and T. Maniatis.
1995.
Signal-induced site-specific phosphorylation targets I B to the ubiquitin-proteasome pathway.
Genes Dev.
9:1586-1597 |
| 8. | Chong, K., L. Feng, T. F. Donahue, J. D. Friesen, E. Meurs, A. G. Hovanessian, and B. R. G. Williams. 1992. Human p68 kinase exhibits growth suppression in yeast and homology to the translational regulator GCN2. EMBO J. 11:1553-1562[Medline]. |
| 9. |
Chu, W. M.,
D. Ostertag,
Z. Li,
L. Chang,
Y. Chen,
Y. Hu,
B. R. G. Williams,
J. Perrault, and M. Karin.
1999.
JNK2 and IKK are required for activating the innate response to viral infection.
Immunity
11:721-731[CrossRef][Medline].
|
| 10. | Clemens, M. J., and E. Androulla. 1997. The double-stranded RNA-dependent protein kinase PKR: structure and function. J. Interferon Res. 17:503-524. |
| 11. | Clemens, M. J., and U. A. Bommer. 1999. Translational control: the cancer connection. Int. J. Biochem. Cell Biol. 31:1-23[CrossRef][Medline]. |
| 12. |
Courtois, G.,
S. T. Whiteside,
C. H. Sibley, and A. Israel.
1997.
Characterization of a mutant cell line that does not activate NF- B in response to multiple stimuli.
Mol. Cell. Biol.
17:1441-1449[Abstract].
|
| 13. |
Craig, A.,
G. Cosentino,
O. Donze, and N. Sonenberg.
1996.
The kinase insert domain of interferon-induced protein kinase PKR is required for activity but not for interaction with the pseudosubstrate K3L.
J. Biol. Chem.
271:24526-24533 |
| 14. |
Dever, T. E.,
J. J. Chen,
G. N. Barber,
A. M. Cigan,
L. Feng,
T. F. Donahue,
I. M. London,
M. G. Katze, and A. G. Hinnebusch.
1993.
Mammalian eIF-2 kinases functionally substitute for GCN2 and stimulate GCN4 translation in yeast.
Proc. Natl. Acad. Sci. USA
90:4616-4620 |
| 15. |
DiDonato, J. A.,
M. Hayakawa,
D. M. Rothwarf,
E. Zandi, and M. Karin.
1997.
A cytokine-responsive I B kinase that activates the transcription factor NF- B.
Nature
388:548-554[CrossRef][Medline].
|
| 16. |
Duh, E. J.,
W. J. Maury,
T. M. Folks,
A. S. Fauci, and A. B. Rabson.
1989.
Tumor necrosis factor activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF- B sites in the long terminal repeat.
Proc. Natl. Acad. Sci. USA
86:5974-5978 |
| 17. | Everett, H., and G. McFadden. 1999. Apoptosis: an innate immune response to virus infection. Trends Microbiol. 7:160-165[CrossRef][Medline]. |
| 18. |
Gil, J.,
J. Alcami, and M. Esteban.
1999.
Induction of apoptosis by double-stranded-RNA-dependent protein kinase (PKR) involves the subunit of eukaryotic translation initiation factor 2 and NF- B.
Mol. Cell. Biol.
19:4653-4663 |
| 19. | Harding, H. P., Y. Zhang, and D. Ron. 1999. Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. Nature 397:271-274[CrossRef][Medline]. |
| 20. |
Henkel, T.,
U. Zabel,
K. Van Zee,
J. Muller,
E. Fanning, and P. A. Baeuerle.
1992.
Intramolecular masking of the nuclear location signal and dimerization domain in the precursor for the p50 NF- B subunit.
Cell
68:1121-1133[CrossRef][Medline].
|
| 21. | Hershey, J. W. 1991. Translational control in mammalian cells. Annu. Rev. Biochem. 60:717-755[CrossRef][Medline]. |
| 22. | Hovanessian, A. G. 1989. The double-stranded RNA-activated protein kinase induced by interferon: dsRNA-PK. J. Interferon Res. 9:641-647[Medline]. |
| 23. | Hsu, H., J. Huang, H.-B. Shu, V. Baichwal, and D. V. Goeddel. 1996. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 4:387-396[CrossRef][Medline]. |
| 24. |
Hu, Y.,
V. Baud,
M. Delhase,
P. Zhang,
T. Deerinck,
M. Ellisman,
R. Johnson, and M. Karin.
1999.
Abnormal morphogenesis but intact IKK activation in mice lacking the IKK subunit of the I B kinase.
Science
284:316-320 |
| 25. |
Iordanov, M. S.,
J. M. Paranjape,
A. Zhou,
J. Wong,
B. R. G. Williams,
E. F. Meurs,
R. H. Silverman, and B. E. Magun.
2000.
Activation of p38 mitogen-activated protein kinase and c-jun NH2-terminal kinase by double-stranded RNA and encephalomyocarditis virus: involvement of RNase L, protein kinase R, and alternative pathways.
Mol. Cell. Biol.
20:617-627 |
| 26. |
Katze, M. G.,
M. Wambach,
M. L. Wong,
M. Garfinkel,
E. Meurs,
K. Chong,
B. R. G. Williams,
A. G. Hovanessian, and G. N. Barber.
1991.
Functional expression and RNA binding analysis of the interferon-induced, double-stranded RNA-activated 68,000-Mr protein kinase in a cell-free system.
Mol. Cell. Biol.
11:5497-5505 |
| 27. |
Knighton, D. R.,
J. H. Zheng,
L. F. Ten Eyck,
N. H. Xuong,
S. S. Taylor, and J. M. Sowadski.
1991.
Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase.
Science
253:414-420 |
| 28. |
Kopp, E., and S. Gosh.
1995.
NF- B: ten years after.
Adv. Immunol.
58:1-27[Medline].
|
| 29. |
Kumar, A.,
J. Haque,
J. Lacoste,
J. Hiscott, and B. R. G. Williams.
1994.
The dsRNA-dependent protein kinase, PKR, activates transcription factor NF- B by phosphorylating I B.
Proc. Natl. Acad. Sci. USA
91:6288-6292 |
| 30. |
Kumar, A.,
Y. L. Yang,
V. Flati,
S. Der,
S. Kadereit,
A. Deb,
J. Hapque,
L. Reis,
C. Weissmann, and B. R. Williams.
1996.
Deficient cytokine signaling in mouse embryo fibroblasts with a targeted deletion in the PKR gene: role of IRF-1 and NF- B.
EMBO J.
16:406-416[CrossRef][Medline].
|
| 31. |
Laurent, A. G.,
B. Krust,
J. Galabru,
J. Svab, and A. G. Hovanessian.
1985.
Monoclonal antibodies to interferon induced 68,000 Mr protein and their use for the detection of double-stranded RNA dependent protein kinase in human cells.
Proc. Natl. Acad. Sci. USA
82:4341-4345 |
| 32. |
Lee, F.,
J. Hagler,
Z. Chen, and T. Maniatis.
1997.
Activation of the I B complex by MEKK1, a kinase of the JNK pathway.
Cell
88:213-222[CrossRef][Medline].
|
| 33. |
Li, Q.,
D. Van Antwerp,
F. Mercurio,
K. Lee, and I. Verma.
1999.
Severe liver degeneration in mice lacking the I B kinase 2 gene.
Science
284:321-325 |
| 34. |
Li, X.,
M. Commane,
C. Burns,
K. Vithalani,
Z. Cao, and G. R. Stark.
1999.
Mutant cells that do not respond to interleukin-1 (IL-1) reveal a novel role for IL-1 receptor-associated kinase.
Mol. Cell. Biol.
19:4643-4652 |
| 35. |
Li, X. L.,
J. A. Blackford, and B. A. Hassel.
1998.
RNase L mediates the antiviral effect of interferon through a selective reduction in viral RNA during encephalomyocarditis virus infection.
J. Virol.
72:2752-2759 |
| 36. |
Malinin, N.,
M. Boldin,
A. Kovalenko, and D. Wallach.
1997.
MAP3K-related kinase involved in NF- B induction by TNF, CD95 and IL-1.
Nature
385:540-544[CrossRef][Medline].
|
| 37. | Mamane, Y., C. Heylbroeck, P. Génin, M. Algarté, M. J. Servant, C. LePage, C. DeLuca, H. Kwon, R. Lin, and J. Hiscott. 1999. Interferon regulatory factors: the next generation. Gene 237:1-14[CrossRef][Medline]. |
| 38. |
Maran, A.,
R. K. Maitra,
A. Kumar,
B. Dong,
W. Xiao,
G. Li,
B. R. Williams,
P. F. Torrence, and R. H. Silverman.
1994.
Blockage of NF-kappa B signaling by selective ablation of an mRNA target by 2-5A antisense chimeras.
Science
265:789-792 |
| 39. |
Maran, A.,
C. F. Waller,
J. M. Paranjape,
G. Li,
W. Xiao,
K. Zhang, et al.
1998.
2',5'-Oligoadenylate-antisense chimeras cause RNAse L to selectively degrade bcr/abl mRNA in chronic myelogenous leukemia cells.
Blood
92:4336-4343 |
| 40. |
McCarthy, J. V.,
J. Ni, and V. M. Dixit.
1998.
RIP2 is a novel NF- B-activating and cell death-inducing kinase.
J. Biol. Chem.
273:16968-16975 |
| 41. |
Mercurio, F.,
H. Zhu,
B. Murray,
A. Shevchenko,
B. Bennett,
J. Li,
D. Young,
M. Barbosa,
M. Mann,
A. Manning, and A. Rao.
1997.
IKK-1 and IKK-2: cytokine-activated I B kinases essential for NF- B activation.
Science
278:860-866 |
| 42. | Meurs, E., K. Chong, J. Galabru, S. B. Thomas, I. M. Kerr, B. R. G. Williams, and A. G. Hovanessian. 1990. Molecular cloning and characterization of cDNA encoding human double-stranded RNA activated protein kinase induced by interferon. Cell 62:379-390[CrossRef][Medline]. |
| 43. | Meurs, E. F., N. McMillan, B. R. Williams, A. G. Hovanessian, and P. J. Southern. 1995. Human PKR transfected into murine cells stimulates expression of genes under control of the HIV1 or HTLV-1 LTR. Virology 214:653-659[CrossRef][Medline]. |
| 44. |
Meurs, E. F.,
Y. Watanabe,
S. Kadereit,
G. N. Barber,
M. G. Katze,
K. Chong,
B. R. G. Williams, and A. G. Hovanessian.
1992.
Constitutive expression of human double-stranded RNA-activated p68 kinase in murine cells mediates phosphorylation of eucaryotic initiation factor 2 and partial resistance to encephalomyocarditis virus growth.
J. Virol.
66:5805-5814 |
| 45. |
Munoz, E.,
G. Courtois,
P. Veschambre,
P. Jalinot, and A. Israel.
1994.
Tax induces nuclear translocation of NF- B through dissociation of cytoplasmic complexes containing p105 or p100 but does not induce degradation of I B /MAD3.
J. Virol.
68:8035-8044 |
| 46. | Nagai, K., A. Hoi-Tao Wong, S. Li, N. Wai Ning Tam, A. R. Cuddihy, N. Sonenberg, M. B. Mathews, J. Hiscott, M. A. Wainberg, and A. E. Koromilas. 1997. Induction of CD4 expression and human immunodeficiency virus type 1 replication by mutants of the interferon-inducible protein kinase PKR. J. Virol. 71:1718-1725[Abstract]. |
| 47. |
Patel, R. C.,
P. Stanton, and G. C. Sen.
1996.
Specific mutations near the amino terminus of double-stranded RNA-dependent protein kinase (PKR) differentially affect its double-stranded RNA binding and dimerization properties.
J. Biol. Chem.
271:25657-25663 |
| 48. | Regnier, C. H., H. Y. Song, X. Gao, D. V. Goeddel, Z. Cao, and M. Rothe. 1997. Identification and characterization of an IkappaB kinase. Cell 90:373-383[CrossRef][Medline]. |
| 49. |
Rothwarf, D.,
E. Zandi,
G. Natoli, and M. Karin.
1998.
IKK- is an essential regulatory subunit of the I B kinase complex.
Nature
395:297-300[CrossRef][Medline].
|
| 50. | Samuel, C. E. 1991. Antiviral actions of interferon. Interferon-regulated cellular proteins and their surprisingly selective antiviral activities. Virology 183:1-11[CrossRef][Medline]. |
| 51. |
Santoyo, J.,
J. Alcalde,
R. Mendez,
D. Pulido, and C. De Haro.
1997.
Cloning and characterization of a cDNA encoding a protein synthesis initiation factor-2 (eIF-2 ) kinase from Drosophila melanogaster.
J. Biol. Chem.
272:12544-12550 |
| 52. |
Seeler, J. S.,
A. Marchio,
D. Sitterlin,
C. Transy, and A. Dejean.
1998.
Interaction of SP100 with HP1 proteins: a link between the promyelocytic leukemia-associated nuclear bodies and the chromatin compartment.
Proc. Natl. Acad. Sci. USA
95:7316-7321 |
| 53. |
Shi, Y.,
K. M. Vattem,
R. Sood,
J. An,
J. Liang,
L. Stramm, and R. C. Wek.
1998.
Identification and characterization of pancreatic eukaryotic initiation factor 2 -subunit, PEK, involved in translational control.
Mol. Cell. Biol.
18:7499-7509 |
| 54. |
Stancovski, I., and D. Baltimore.
1997.
NF- B activation: the I B kinase revealed?
Cell
91:299-302[CrossRef][Medline].
|
| 55. |
Takeda, K.,
O. Takeuchi,
T. Tsujimura,
S. Itami,
O. Adachi,
T. Kawai,
H. Sanjo,
K. Yoshikawa,
N. Terada, and S. Akira.
1999.
Limb and skin abnormalities in mice lacking IKK .
Science
284:313-316 |
| 56. |
Ting, A. T.,
F. X. Pimentel-Muinos, and B. Seed.
1996.
RIP mediates tumor necrosis factor receptor 1 activation of NF- B but not Fas/APO-1-initiated apoptosis.
EMBO J.
15:6189-6196[Medline].
|
| 57. |
Watanabe, M.,
M. Muramatsu,
H. Hirai,
T. Suzuki,
J. Fujisawa,
M. Yoshida,
K. Arai, and N. Arai.
1993.
HTLV-1 encoded Tax in association with NF- B precursor p105 enhances nuclear localization of NF- B p50 and p65 in transfected cells.
Oncogene
8:2949-2958[Medline].
|
| 58. | Williams, B. R. G. 1995. The role of the dsRNA-activated protein kinase, PKR, in signal transduction. Semin. Virol. 6:191-202. |
| 59. |
Yamaoka, S.,
G. Courtois,
C. Bessia,
S. T. Whiteside,
R. Weil,
F. Agout,
H. E. Kirk,
R. J. Kay, and A. Israel.
1998.
Complementation cloning of NEMO, a component of the I B kinase complex essential for NF- B activation.
Cell
93:1231-1240[CrossRef][Medline].
|
| 60. | Yang, Y. L., L. F. Reis, J. Pavlovic, A. Aguzzi, R. Schafer, A. Kumar, B. R. Williams, M. Aguet, and C. Weissmann. 1995. Deficient signaling in mice devoid of double-stranded RNA-dependent protein kinase. EMBO J. 14:6095-6106[Medline]. |
| 61. |
Yaron, A.,
H. Gonen,
I. Alkalay,
A. Hatzubai,
S. Jung,
S. Beyth,
F. Mercurio,
A. Manning,
A. Ciechanover, and Y. Ben-Neriah.
1997.
Inhibition of NF- B cellular function via specific targeting of the I B ubiquitin ligase.
EMBO J.
16:101-107.
|
| 62. |
Yu, P. W.,
B. C. B. Huang,
M. Shen,
J. Quast,
E. Chan,
X. Xu,
G. P. Nolan,
D. G. Payan, and Y. Luo.
1999.
Identification of RIP3, a RIP-like kinase that activates apoptosis and NF- B.
Curr. Biol.
9:539-542[CrossRef][Medline].
|
| 63. |
Zandi, E.,
D. M. Rothwarf,
M. Delhasse,
M. Hayakawa, and M. Karin.
1997.
The I B kinase complex (IKK) contains two kinase subunits, IKK and IKK , necessary for I B phosphorylation and NF- B activation.
Cell
91:243-252[CrossRef][Medline].
|
| 64. | Zhou, A., B. A. Hassel, and R. H. Silverman. 1993. Expression cloning of 2-5A-dependent RNAse: a uniquely regulatory mediator of interferon action. Cell 72:753-765[CrossRef][Medline]. |
| 65. |
Zinn, K.,
A. Keller,
L. A. Whittemore, and T. Maniatis.
1988.
2-Aminopurine selectively inhibits the induction of -interferon, c-fos, and c-myc gene expression.
Science
240:210-213 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»